Thomas Fiß
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Thomas Fiß has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Jochen René Thyrian
German Center for Neurodegenerative Diseases (DZNE), Greifswald, Germany
3 shared publications - Wolfgang Hoffmann
German Center for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, Greifswald, Germany
3 shared publications - Stefan Teipel
German Center for Neurodegenerative Diseases (DZNE) Site Rostock/Greifswald, Rostock, Germany
2 shared publications - Adina Dreier
Institute for Community Medicine, Department Epidemiology of Health Care and Community Health, University Medicine Greifswald, Ellernholzstr. 1-2, 17487 Greifswald, Germany
1 shared publication - Aniela Angelow
Department of General Practice, Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany
1 shared publication - Diana Wucherer
German Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Greifswald, Germany
1 shared publication
Latest Publications
- Open Access
- 13 November 2013
- Published by Springer Nature in BMC Geriatrics
- Vol. 13 (1) , 121
Medication management for people with dementia in primary care: description of implementation in the DelpHi study
Background: As the population ages, the relative and absolute number of age-associated diseases such as dementia will increase. Evaluation of the suitability and intake of medication and pharmacological treatment is an important aspect of care for people with dementia, especially if they live at home. Regular medication reviews and systematic cooperation between physicians and pharmacists are not common in routine care. Medication management (MM), based on such a comprehensive home medication review could help to reduce drug-related problems and costs. The present article presents a medication management specifically for the application in the ambulatory setting and describes its implementation as part of a larger trial. Methods/design: A home medication review (HMR) and MM is implemented as part of the DelpHi study, a population based prospective, cluster-randomized controlled intervention study to test the efficacy and efficiency of the implementation of a collaborative care model in primary care. Participants: people with dementia (PWD) and their caregivers are recruited by the patient’s general practitioner. Inclusion criteria are a positive screening result for dementia, living at home and regular intake of drugs. PWD are asked to specify their regular pharmacy which is asked to participate in the study, too. Intervention: a comprehensive HMR is conducted as computer-assisted personal interview by specifically qualified Dementia Care Manager (DCM) at the people’s home. It includes detailed information about drugs taken, their storage, administration, adherence and adverse events. The MM is conducted in cooperation between DCM, pharmacist and general practitioner and consists of a pharmaceutical evaluation, pharmaceutical recommendations and their application. Pharmacists are trained and provided with regularly updated information. The MM is designed to give information and recommendations concerning antidementia drugs, occurrence of drug related problems, intake of anticholinergic drugs, potentially clinically relevant drug-drug-interactions, adverse drug events and medication adherence. Discussion: The DelpHi-approach for medication management employs comprehensive instruments and procedures in the primary care setting under routine care conditions, and this approach should be useful in improving pharmacotherapy as part of the comprehensive treatment and care for people with dementia. Trial registration: The trial is registered at ClinicalTrials.gov, number NCT01401582.
- 13 November 2013
- Published by Springer Nature in BMC Geriatrics
- Vol. 13 (1) , 121
Open AccessMedication management for people with dementia in primary care: description of implementation in the DelpHi study
Background: As the population ages, the relative and absolute number of age-associated diseases such as dementia will increase. Evaluation of the suitability and intake of medication and pharmacological treatment is an important aspect of care for people with dementia, especially if they live at home. Regular medication reviews and systematic cooperation between physicians and pharmacists are not common in routine care. Medication management (MM), based on such a comprehensive home medication review could help to reduce drug-related problems and costs. The present article presents a medication management specifically for the application in the ambulatory setting and describes its implementation as part of a larger trial. Methods/design: A home medication review (HMR) and MM is implemented as part of the DelpHi study, a population based prospective, cluster-randomized controlled intervention study to test the efficacy and efficiency of the implementation of a collaborative care model in primary care. Participants: people with dementia (PWD) and their caregivers are recruited by the patient’s general practitioner. Inclusion criteria are a positive screening result for dementia, living at home and regular intake of drugs. PWD are asked to specify their regular pharmacy which is asked to participate in the study, too. Intervention: a comprehensive HMR is conducted as computer-assisted personal interview by specifically qualified Dementia Care Manager (DCM) at the people’s home. It includes detailed information about drugs taken, their storage, administration, adherence and adverse events. The MM is conducted in cooperation between DCM, pharmacist and general practitioner and consists of a pharmaceutical evaluation, pharmaceutical recommendations and their application. Pharmacists are trained and provided with regularly updated information. The MM is designed to give information and recommendations concerning antidementia drugs, occurrence of drug related problems, intake of anticholinergic drugs, potentially clinically relevant drug-drug-interactions, adverse drug events and medication adherence. Discussion: The DelpHi-approach for medication management employs comprehensive instruments and procedures in the primary care setting under routine care conditions, and this approach should be useful in improving pharmacotherapy as part of the comprehensive treatment and care for people with dementia. Trial registration: The trial is registered at ClinicalTrials.gov, number NCT01401582.
- Open Access
- 10 May 2012
- Published by Springer Nature in Trials
- Vol. 13 (1) , 56
Life- and person-centred help in Mecklenburg-Western Pomerania, Germany (DelpHi): study protocol for a randomised controlled trial
The provision of appropriate medical and nursing care for people with dementia is a major challenge for the healthcare system in Germany. New models of healthcare provision need to be developed, tested and implemented on the population level. Trials in which collaborative care for dementia in the primary care setting were studied have demonstrated its effectiveness. These studies have been conducted in different healthcare systems, however, so it is unclear whether these results extend to the specific context of the German healthcare system.
- 10 May 2012
- Published by Springer Nature in Trials
- Vol. 13 (1) , 56
Open AccessLife- and person-centred help in Mecklenburg-Western Pomerania, Germany (DelpHi): study protocol for a randomised controlled trial
The provision of appropriate medical and nursing care for people with dementia is a major challenge for the healthcare system in Germany. New models of healthcare provision need to be developed, tested and implemented on the population level. Trials in which collaborative care for dementia in the primary care setting were studied have demonstrated its effectiveness. These studies have been conducted in different healthcare systems, however, so it is unclear whether these results extend to the specific context of the German healthcare system.
- 16 April 2012
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 28 (2) , 173-181
Cognitive impairment in primary ambulatory health care: pharmacotherapy and the use of potentially inappropriate medicine
Objective: Drug intake is associated with a risk of drug‐related problems, for example, the intake of potentially inappropriate medication (PIM), especially for cognitively impaired individuals. The proportion of PIM taken by immobile individuals, especially patients with suspicion of dementia in the AGnES studies (German: Arzt‐entlastende Gemeinde‐nahe E‐Health‐gestützte Systemische Intervention), and possible determinants were analyzed.Methods: In a community‐based, prospective cohort study in the ambulatory healthcare sector, a sample of 342 patients aged ≥65 years were screened for dementia and received a home medication review. The screening for dementia was positive in 111 cases (32.5%). Data assessment included sociodemographic variables and medical diagnoses. The German PRISCUS list was used to detect PIM and drug–condition interactions.Results: Potentially inappropriate medication in dementia was identified in 22 (19.8%) patients with suspicion of dementia. A multivariate binary logistic regression revealed that the number of drugs taken (one to four drugs: OR = 0.059; 95% CI 0.006–0.55, p = 0.0133; Ref.: >9 drugs) and female gender (OR = 10.362; 95% CI: 1.28–83.87) were risk factors for PIM intake in patient with suspicion of dementia.Conclusions: Inappropriate medication use in a community‐based sample positively screened for dementia appears to be determined by sex and the number of drugs taken. The intake of fewer than five drugs and receiving support with regard to drug intake protects from the intake of PIM. Patients could benefit from medication management in a collaborative network of healthcare professionals. The implementation of systematic medication review and drug documentation should be extended and standardized in both research studies and routine primary health care. Copyright © 2012 John Wiley & Sons, Ltd.
- 16 April 2012
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 28 (2) , 173-181
Cognitive impairment in primary ambulatory health care: pharmacotherapy and the use of potentially inappropriate medicine
Objective: Drug intake is associated with a risk of drug‐related problems, for example, the intake of potentially inappropriate medication (PIM), especially for cognitively impaired individuals. The proportion of PIM taken by immobile individuals, especially patients with suspicion of dementia in the AGnES studies (German: Arzt‐entlastende Gemeinde‐nahe E‐Health‐gestützte Systemische Intervention), and possible determinants were analyzed.Methods: In a community‐based, prospective cohort study in the ambulatory healthcare sector, a sample of 342 patients aged ≥65 years were screened for dementia and received a home medication review. The screening for dementia was positive in 111 cases (32.5%). Data assessment included sociodemographic variables and medical diagnoses. The German PRISCUS list was used to detect PIM and drug–condition interactions.Results: Potentially inappropriate medication in dementia was identified in 22 (19.8%) patients with suspicion of dementia. A multivariate binary logistic regression revealed that the number of drugs taken (one to four drugs: OR = 0.059; 95% CI 0.006–0.55, p = 0.0133; Ref.: >9 drugs) and female gender (OR = 10.362; 95% CI: 1.28–83.87) were risk factors for PIM intake in patient with suspicion of dementia.Conclusions: Inappropriate medication use in a community‐based sample positively screened for dementia appears to be determined by sex and the number of drugs taken. The intake of fewer than five drugs and receiving support with regard to drug intake protects from the intake of PIM. Patients could benefit from medication management in a collaborative network of healthcare professionals. The implementation of systematic medication review and drug documentation should be extended and standardized in both research studies and routine primary health care. Copyright © 2012 John Wiley & Sons, Ltd.
- 11 May 2011
- Published by Georg Thieme Verlag KG in Das Gesundheitswesen
- Vol. 74 (05) , 322-327
Zeitbedarf und Kosten für die Umsetzung eines Medikamentenreviews und assoziierter pharmazeutischer und medizinischer Evaluation im ambulanten Versorgungssektor
Einleitung: Berechnung des Zeitbedarfs und Kostenschätzung für die Durchführung eines Medikationsreviews im Rahmen der AGnES-Studien (Arzt-entlastende Gemeinde-nahe E-health-gestützte systemische Intervention). Methoden: AGnES-Fachkräfte führten ein IT-gestütztes, systematisches Medikationsreview bei Hausbesuchspatienten durch. Ziel des Medikationsreviews war die Erfassung und Lösung ausgewählter arzneimittelbezogener Probleme (ABP) in Kooperation mit Apotheke und Arzt. Ergebnisse: Die Daten von 471 Patienten (w: 339; m: 132) wurden ausgewertet (Medianes Alter w=81; m=78). Das allgemeine Interview zu ABP dauerte im Median 6 min, die Medikamentenerfassung 14,4 min Hinzu kamen 5 min für den Dokumentationsaufwand der AGnES-Fachkraft. Die Auswertung des Apothekers dauerte 15 min und die des Arztes 8 min (Median). Für eine Datenerfassung durch die AGnES-Fachkraft (9,12 €) und Bewertung durch einen Apotheker (11,05 €) und Arzt (6,30 €) entstünden mediane Kosten in Höhe von 26,47 €. Schlussfolgerung: Erstmals werden objektive Daten zur Dauer und Kosten eines Medikationsreviews präsentiert. Angesichts der erheblichen ABP verursachten Kosten ermöglicht die flächendeckende Implementierung von systematischen Medikationsreviews bei Risikogruppen relevante Ressourceneinsparungen. Introduction: We aimed to estimate the time which is needed to conduct a home medication review (HMR) in the context of the AGnES implementation studies (AGnES=GP-supporting, community-based, e-health-assisted, systemic intervention). In a subsequent step associated costs were calculated. Methods: IT-supported HMR were conducted by specially qualified AGnES-practice assistants to detect selected drug-related problems (DRP). The patient received pharmaceutical care by their local pharmacist and medical evaluation by their GP, respectively. Results: The data from 471 patients (w: 339; m: 132) were evaluated (median age: w=81; m=78). The interview to detect selected DRP was 6 min (median) long. The subsequent drug record took 14.4 min. There was an additional effort for documentation of 5 min. The local pharmacist needed a median time of 15 min for pharmaceutical evaluation, whereas the GP needed 8 min. The estimated costs accounted for: AGnES-practice assistant: 9.12 €; pharmacist: 11.05 €; GP: 6.30 €. The overall estimated costs were 26.47 €. Conclusion: For the first time we present objective costs which were associated with the implementation of HMR. Due to high DRP-induced costs the HMR should be mandatory for groups with a high risk like for the occurrence of DRP.
- 11 May 2011
- Published by Georg Thieme Verlag KG in Das Gesundheitswesen
- Vol. 74 (05) , 322-327
Zeitbedarf und Kosten für die Umsetzung eines Medikamentenreviews und assoziierter pharmazeutischer und medizinischer Evaluation im ambulanten Versorgungssektor
Einleitung: Berechnung des Zeitbedarfs und Kostenschätzung für die Durchführung eines Medikationsreviews im Rahmen der AGnES-Studien (Arzt-entlastende Gemeinde-nahe E-health-gestützte systemische Intervention). Methoden: AGnES-Fachkräfte führten ein IT-gestütztes, systematisches Medikationsreview bei Hausbesuchspatienten durch. Ziel des Medikationsreviews war die Erfassung und Lösung ausgewählter arzneimittelbezogener Probleme (ABP) in Kooperation mit Apotheke und Arzt. Ergebnisse: Die Daten von 471 Patienten (w: 339; m: 132) wurden ausgewertet (Medianes Alter w=81; m=78). Das allgemeine Interview zu ABP dauerte im Median 6 min, die Medikamentenerfassung 14,4 min Hinzu kamen 5 min für den Dokumentationsaufwand der AGnES-Fachkraft. Die Auswertung des Apothekers dauerte 15 min und die des Arztes 8 min (Median). Für eine Datenerfassung durch die AGnES-Fachkraft (9,12 €) und Bewertung durch einen Apotheker (11,05 €) und Arzt (6,30 €) entstünden mediane Kosten in Höhe von 26,47 €. Schlussfolgerung: Erstmals werden objektive Daten zur Dauer und Kosten eines Medikationsreviews präsentiert. Angesichts der erheblichen ABP verursachten Kosten ermöglicht die flächendeckende Implementierung von systematischen Medikationsreviews bei Risikogruppen relevante Ressourceneinsparungen. Introduction: We aimed to estimate the time which is needed to conduct a home medication review (HMR) in the context of the AGnES implementation studies (AGnES=GP-supporting, community-based, e-health-assisted, systemic intervention). In a subsequent step associated costs were calculated. Methods: IT-supported HMR were conducted by specially qualified AGnES-practice assistants to detect selected drug-related problems (DRP). The patient received pharmaceutical care by their local pharmacist and medical evaluation by their GP, respectively. Results: The data from 471 patients (w: 339; m: 132) were evaluated (median age: w=81; m=78). The interview to detect selected DRP was 6 min (median) long. The subsequent drug record took 14.4 min. There was an additional effort for documentation of 5 min. The local pharmacist needed a median time of 15 min for pharmaceutical evaluation, whereas the GP needed 8 min. The estimated costs accounted for: AGnES-practice assistant: 9.12 €; pharmacist: 11.05 €; GP: 6.30 €. The overall estimated costs were 26.47 €. Conclusion: For the first time we present objective costs which were associated with the implementation of HMR. Due to high DRP-induced costs the HMR should be mandatory for groups with a high risk like for the occurrence of DRP.
- 17 December 2010
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 107 (50) , 899-900
Definition of Age
The PRISCUS list lacks a vital piece of information. The issue under discussion is inappropriate medications for elderly patients, but age is specified neither in terms of years nor in terms of a clinically more adequate characterization. This means...
- 17 December 2010
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 107 (50) , 899-900
Definition of Age
The PRISCUS list lacks a vital piece of information. The issue under discussion is inappropriate medications for elderly patients, but age is specified neither in terms of years nor in terms of a clinically more adequate characterization. This means...